Lisanti Capital Growth LLC Makes New Investment in Repligen Corporation $RGEN

Lisanti Capital Growth LLC purchased a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 19,460 shares of the biotechnology company’s stock, valued at approximately $3,189,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Repligen by 1.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock worth $584,000 after buying an additional 75 shares in the last quarter. NewEdge Wealth LLC grew its position in Repligen by 5.3% in the 4th quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 75 shares during the period. UMB Bank n.a. grew its position in Repligen by 17.0% in the 3rd quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 97 shares during the period. CANADA LIFE ASSURANCE Co grew its position in Repligen by 0.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock valued at $4,542,000 after purchasing an additional 100 shares during the period. Finally, Northwestern Mutual Investment Management Company LLC grew its position in Repligen by 1.0% in the 3rd quarter. Northwestern Mutual Investment Management Company LLC now owns 11,787 shares of the biotechnology company’s stock valued at $1,576,000 after purchasing an additional 121 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on RGEN. Canaccord Genuity Group reduced their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Wells Fargo & Company reduced their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Weiss Ratings raised shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 7th. KeyCorp reissued an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Finally, Royal Bank Of Canada began coverage on shares of Repligen in a research report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $166.15.

Repligen Price Performance

RGEN opened at $115.06 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The company has a market capitalization of $6.49 billion, a price-to-earnings ratio of 127.85, a P/E/G ratio of 2.22 and a beta of 1.09. The firm’s fifty day moving average price is $117.74 and its two-hundred day moving average price is $140.77. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $175.77.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The firm had revenue of $194.26 million for the quarter, compared to the consensus estimate of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.